Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Judge Wields Pre-emption To Dismiss Medtronic Fidelis Claims

This article was originally published in The Gray Sheet

Executive Summary

A Minnesota federal judge on Jan. 5 categorically 1dismissed on grounds of federal pre-emption all 21 claims in a multidistrict personal injury lawsuit against Medtronic for its Sprint Fidelis implantable defibrillator leads

You may also be interested in...



News In Brief

Comprehensive Fidelis settlement

News In Brief

Comprehensive Fidelis settlement

Another Fidelis dismissal

Minnesota state judge dismisses more than 600 personal injury suits, including 14 distinct liability claims, against Medtronic related to its discontinued 7-French Sprint Fidelis defibrillator lead. The Oct. 20 dismissal 1order cites federal pre-emption protection for the FDA-approved product and follows a similar ruling in January in federal multi-district litigation (2"The Gray Sheet" Jan. 12, 2009). In both cases, the judges rejected plaintiffs' arguments that their claims were "parallel" to rather than in addition to FDA requirements and that the Class I recall of Fidelis invalidated its PMA supplement approval. Legislation to reverse the 2008 U.S. Supreme Court decision that forms the basis of these rulings is still pending in Congress (3"The Gray Sheet" Aug. 10, 2009)

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel